NCT00183092 is a Phase 2 clinical trial of Quinacrine in Creutzfeldt-Jakob Disease, sponsored by University of California, San Francisco.

Who is sponsoring NCT00183092?

NCT00183092 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT00183092?

Interventions in NCT00183092: Quinacrine, Placebo.

What condition does NCT00183092 study?

NCT00183092 studies Creutzfeldt-Jakob Disease.

Is NCT00183092 still recruiting?

NCT00183092 is currently completed. Last updated 28 May 2014.

Are results published for NCT00183092?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-05-28 · How we verify

NCT00183092

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease

Completed Phase 2 Results posted Last updated 28 May 2014

What this trial tests

Phase 2 trial testing Quinacrine in Creutzfeldt-Jakob Disease in 69 participants. Completed in 1 June 2012.

Timeline

1 April 2005

Primary endpoint
1 June 2012

1 June 2012

Quick facts

Lead sponsor	University of California, San Francisco
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	69
Start date	1 April 2005
Primary completion	1 June 2012
Estimated completion	1 June 2012
Sites	1 location across United States

Drugs / interventions tested

Quinacrine — full drug profile →
Placebo

Conditions studied

Creutzfeldt-Jakob Disease — all drugs for Creutzfeldt-Jakob Disease →

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Creutzfeldt-Jakob Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Primary Survival
Time frame: Randomization to Month-2
Participants alive after 2 months on study treatment

Sponsor's own description

The purpose of this clinical trial is to determine the effectiveness of the medication quinacrine on survival in sporadic Creutzfeldt-Jakob disease (sCJD).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.
Al-Bari MA. · · 2015 · cited 293× · PMID 25693996 · DOI 10.1093/jac/dkv018
Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.
Geschwind MD, Kuo AL, Wong KS, Haman A, et al · · 2013 · cited 99× · PMID 24122181 · DOI 10.1212/wnl.0b013e3182a9f3b4
Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.
Ehsanian R, Van Waes C, Feller SM. · · 2011 · cited 98× · PMID 21569639 · DOI 10.1186/1478-811x-9-13
Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.
Salas Rojas M, Silva Garcia R, Bini E, Pérez de la Cruz V, et al · · 2021 · cited 17× · PMID 33477376 · DOI 10.3390/v13010121
Quinacrine, an Old Drug with Potentially usefull in the Treatment for COVID-19.
Pineda B. · · 2021 · cited 1× · PMID 34154830 · DOI 10.1016/j.arcmed.2021.06.002

Verify or expand the search:

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00183092 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 28 May 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00183092.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing